The company will continue clinical trials of the drug after its appearance on the market in a new way.
Chinese pharmaceutical company Zhejiang Hisun Pharmaceutical said that it has received from the authorities permission to sell the drug Favipiravir as a potential cure for coronavirus.
The company said that it will continue clinical trials of the drug after its market launch in new capacity, according to Reuters.
As stated by the Director of the Center for biotechnology development under the Chinese Ministry of science and technology of China Zhang Xinmin, in clinical trials of Favipiravir was attended by 70 patients, writes China.org.
According to the preliminary data, the drug has a relatively obvious efficiency and low likelihood of causing side effects. Similar tests are several remedies.
World health organization 30 January 2020 declared emergency situation of international importance in connection with the spread of coronavirus from China.
As of February 16 in the world was 69 261 laboratory-confirmed case of new coronavirus infection COVID-19, of which 1669 – lethal.
In Ukraine, a single laboratory-confirmed case COVID-19 is not fixed.